Are These The Best Biotech Stocks In 2020?
Biotech stocks have been on fire thanks to speculation about potential vaccines or treatments for Covid-19. Everyday investors wake up with the hope that a vaccine has been found. We all are because we know that such news would prop up the stock market. I get it, the pandemic-driven frenzy has made it really hard for investors to focus on the fundamentals of certain pharmaceutical stocks. My point is, while many focus their attention on the insidious virus, there are also major breakthroughs that are not related to Covid-19.
Why Fundamentals Are So Important In Biotech Stocks
The race for the Covid-19 vaccine has seen pharmaceutical stocks scaling up their manufacturing. This is even before the vaccine candidates are proven to be safe and effective. After you see such headlines, that particular stock is already making a huge rally. This week, we are seeing this scenario with Vaxart (VRTX Stock Report) and other biotech companies making huge jumps after receiving funding to scale up their vaccine production.
Let me say it once more. These vaccines are not the answer to the novel coronavirus just yet. Don’t get me wrong though. They have shown remarkable results during clinical trials. What I’m saying is despite showing potentials, markets are reacting like it is “the vaccine” for the pandemic. Of course, this carries huge financial risks. You tell me, what would happen when the vaccine is ready and it doesn’t work as hoped? If this is something you can’t stomach, there are still plenty of top biotech stocks that are worth the attention.
With vaccines or potential treatments seeming like far-flung dreams, should we focus on biotech stocks that are currently showing promising signs in other diseases? For this reason, let’s take a look at certain biotech stocks that are making big moves this week.
Read More
- 2 Top Tech Stocks To Watch During The COVID-19 Pandemic
- Teladoc Health (TDOC): Is It Too Late For Virtual Health Care Stocks?
- Are These 2 Top Retail Stocks Set To Rebound Post COVID-19?
Best Biotech Stocks 2020: Ekso Bionics
Shares of Ekso Bionics (EKSO Stock Report) had an epic rally on Thursday. Most of us witnessed the aggressive breakout of the company. The stock saw a 184x surge in volume compared to its usual average volume. This came after the announcement that the FDA has approved the company’s robotic exoskeleton EksoNR for use in patients with acquired brain injury.
“At Ekso Bionics, we are committed to maximizing patient access to our technology. With the expanded indications to include the broad category of acquired brain injuries, the EksoNR has the potential to mobilize significantly more patients and improve patient recovery,” said Jack Peurach, CEO and president of Ekso Bionics. “Based on their experience with EksoNR, customers at leading rehabilitation centers have acknowledged the benefits our technology can offer during recovery from brain injuries. We are excited to see the device used more widely in neurorehabilitation.”
EksoNR saw a whopping 135% increase in share price during the day. That’s not a surprise though. EksoNR is the next generation device of the most used robotic exoskeleton, and was previously cleared by the FDA for stroke and spinal cord injury rehabilitation in 2016. The device was the first of its kind to receive approval for stroke indication. Now, it is also the first to receive approval for ABI indication. Many experts believe that there’s huge potential upside in EKSO stock. With all that in mind, is EKSO stock attractive enough to be part of your portfolio?
[Read More] 2 Pharmaceutical Stocks To Watch In 2020; 1 Up 73.08% YTD
Best Biotech Stocks 2020: Acadia Pharmaceuticals Inc.
The market has been high on Acadia Pharmaceuticals (ACAD Stock Report). That is simply due to its impressive first-quarter performance of its Parksin drug, Nuplazid. The company started to attract investors’ attention after reporting a 43% increase in sales year over year to $91 million. On top of that, a potential label expansion to treat a much larger population of patients with dementia-related psychosis (DRP) could be huge. This could put the company into a position to enjoy a further boost in sales of its Nuplazid drug.
Acadia’s operations are close to being profitable with Nuplazid as a treatment for the limited Parkinson’s disease population. Many analysts believe that the market hasn’t priced in the drug’s high potential of success as a treatment for the much larger population with DRP. As such, should investors stock up some ACAD shares now and wait for it to grow when Nuplazid is approved for DRP?
